BioLineRx Ltd. (BLRX)
BioLineRx Ltd. Statistics
Share Statistics
BioLineRx Ltd. has 3.72M shares outstanding. The number of shares has increased by 53.13% in one year.
| Shares Outstanding | 3.72M |
| Shares Change (YoY) | 53.13% |
| Shares Change (QoQ) | 27.18% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 3.7M |
| Failed to Deliver (FTD) Shares | 69 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 1.06M, so 0.73% of the outstanding shares have been sold short.
| Short Interest | 1.06M |
| Short % of Shares Out | 0.73% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 2.39 |
Valuation Ratios
The PE ratio is -1.72 and the forward PE ratio is -0.99. BioLineRx Ltd.'s PEG ratio is -0.01.
| PE Ratio | -1.72 |
| Forward PE | -0.99 |
| PS Ratio | 21.7 |
| Forward PS | 0.9 |
| PB Ratio | 7.88 |
| P/FCF Ratio | -4.55 |
| PEG Ratio | -0.01 |
Enterprise Valuation
BioLineRx Ltd. has an Enterprise Value (EV) of 108.17M.
| EV / Earnings | -1.78 |
| EV / Sales | 22.54 |
| EV / EBITDA | -1.9 |
| EV / EBIT | -2.18 |
| EV / FCF | -4.72 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.53 |
| Quick Ratio | 1.47 |
| Debt / Equity | 0.88 |
| Total Debt / Capitalization | 46.71 |
| Cash Flow / Debt | -1.95 |
| Interest Coverage | -23.18 |
Financial Efficiency
Return on equity (ROE) is -4.58% and return on capital (ROIC) is -200.27%.
| Return on Equity (ROE) | -4.58% |
| Return on Assets (ROA) | -0.95% |
| Return on Capital (ROIC) | -200.27% |
| Revenue Per Employee | $60,759.49 |
| Profits Per Employee | $-767,265.82 |
| Employee Count | 79 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 1.89 |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -93.25% in the last 52 weeks. The beta is 0.93, so BioLineRx Ltd.'s price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | -93.25% |
| 50-Day Moving Average | 4.51 |
| 200-Day Moving Average | 17.8 |
| Relative Strength Index (RSI) | 36.37 |
| Average Volume (20 Days) | 234.24K |
Income Statement
In the last 12 months, BioLineRx Ltd. had revenue of 4.8M and earned -60.61M in profits. Earnings per share was -0.06.
| Revenue | 4.8M |
| Gross Profit | 1.11M |
| Operating Income | -49.69M |
| Net Income | -60.61M |
| EBITDA | -57.06M |
| EBIT | -49.69M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 4.25M in cash and 11.59M in debt, giving a net cash position of -7.34M.
| Cash & Cash Equivalents | 4.25M |
| Total Debt | 11.59M |
| Net Cash | -7.34M |
| Retained Earnings | -390.61M |
| Total Assets | 52.74M |
| Working Capital | 12.89M |
Cash Flow
In the last 12 months, operating cash flow was -22.61M and capital expenditures -297K, giving a free cash flow of -22.91M.
| Operating Cash Flow | -22.61M |
| Capital Expenditures | -297K |
| Free Cash Flow | -22.91M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 23.08%, with operating and profit margins of -1.04K% and -1.26K%.
| Gross Margin | 23.08% |
| Operating Margin | -1.04K% |
| Pretax Margin | -1.26K% |
| Profit Margin | -1.26K% |
| EBITDA Margin | -1.19K% |
| EBIT Margin | -1.04K% |
| FCF Margin | -477.19% |
Dividends & Yields
BLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.9% |
| FCF Yield | -194.8% |
Analyst Forecast
The average price target for BLRX is $220, which is 6862% higher than the current price. The consensus rating is "Buy".
| Price Target | $220 |
| Price Target Difference | 6862% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 30, 2025. It was a backward split with a ratio of 1:40.
| Last Split Date | Jan 30, 2025 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -10.62 |
| Piotroski F-Score | 2 |